Our study further investigates the role of NFE2L1 in gliomas by clarifying the intricate relationship between its expression and the polarization of TAMs within the glioma microenvironment, thereby underscoring the potential of NFE2L1 as a viable therapeutic target for glioma treatment. This evidence concerns the gene NFE2L1 and central nervous system cancer.